Novartis AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NOTA.F | AMGN | AZN | BIIB | MRK | SNY | |
|---|---|---|---|---|---|---|
| Market cap | 258.50B | 237.31B | 261.82B | 35.92B | 365.88B | 99.20B |
| P/E (TTM) | 24.3 | 27.3 | 25.2 | 43.2 | 117.7 | 21.8 |
| Forward P/E | 20.1 | 17.9 | 14.9 | 14.8 | 16.0 | 7.8 |
| Price/book | 7.0 | 20.3 | 5.2 | 1.9 | 8.7 | 1.3 |
| Dividend yield | 3.07% | 2.30% | 1.90% | — | 2.29% | 5.84% |
| 1-year change | +18.22% | +45.76% | +1.43% | +64.57% | +69.27% | −16.63% |
| Today | +0.74% | +3.29% | +2.97% | +4.12% | +3.25% | +4.62% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All NOTA.F news ›Novartis: The Sell-Off Creates An Attractive Entry Point
Novartis Q3 earnings Oct 27: revenue growth, oncology strength & Cosentyx EMA news. Click here to read my most recent analysis of NVS stock. - On October 27, Novartis will report its results for the third quarter. - As a reminder, its Q2…
Emad Shash: Welcoming Novartis Egypt Leaders to Cairo University’s Breast Cancer Center
Emad Shash, Leading Cancer Researcher and Director at National Cancer Institute, shared on LinkedIn: It was a great pleasure today to welcome Jihane Hatem El Murr, Country President of Novartis Egypt, together with Moheyeldin Magdy Head of…
Novartis abandons Fabhalta trial in lupus nephritis
A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for its oral complement inhibitor Fabhalta to include lupus nephritis. According to an update on the clinicaltrials.gov registry website, Novartis…
Enterprise value to revenue forward of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology,…
Novartis Has Five Fast-Growing Drugs, but Is Its Valuation Asking Too Much?
Novartis is generating impressive sales from newer medicines, but generic competition is consuming much of that growth. Its earnings valuation makes the gap difficult to ignore. The stock closed at $143.75 on October 9, with Yahoo…
Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis
Novartis (NVS) ends a mid-stage trial for kidney drug Fabhalta (iptacopan) in lupus nephritis because of strategic considerations. Read more here. TBE/iStock Editorial via Getty Images Novartis (NVS) has terminated a mid-stage trial for…
Novartis in Society Integrated Report
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
The Novartis US Foundation
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
• The trial was evaluating whether the oral medication was safe and effective for treating lupus nephritis when added to standard medical care • Lupus nephritis is a severe inflammation of the kidneys caused by the autoimmune disease lupus…
Novartis commitment to patients and caregivers
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com26
-
tradingview.com6
-
biospace.com3
-
medicaldialogues.in3
-
news.bloomberglaw.com3
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 118 articles, not a forecast.